SCHEMBL188526

SCHEMBL188526

Cn1ncc(Cl)c1C1=C(Cl)C=C(C(=O)N[C@H](CN)Cc2cccc(F)c2)C(=S)C1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 10/20 0.63
AKT2 P31751 4/20 0.63
AKT3 Q9Y243 4/20 0.63
ROCK1 Q13464 4/20 0.63
PRKCA P17252 3/20 0.63
ROCK2 O75116 2/20 0.63
PRKCB P05771 2/20 0.63
PRKACA P17612 2/20 0.63
PRKACB P22694 2/20 0.63
PKN1 Q16512 2/20 0.63
PRKD2 Q9BZL6 2/20 0.63
CIT O14578 1/20 0.63
SGK1 O00141 1/20 0.49
PRKD3 O94806 1/20 0.49
LATS1 O95835 1/20 0.49
PRKCG P05129 1/20 0.49
RPS6KB1 P23443 1/20 0.49
PRKCH P24723 1/20 0.49
MARK3 P27448 1/20 0.49
PRKCI P41743 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16224054 0.99 AKT1 (0.62) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL15810194 0.93 AKT1 (0.62) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL15809898 0.93 AKT1 (0.56) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL15810090 0.92 AKT1 (0.55) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL15810078 0.91 AKT1 (0.59) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL15810190 0.91 ROCK1 (0.53) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL15810056 0.91 AKT1 (0.51) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL15810149 0.90 AKT1 (0.50) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL15810043 0.90 AKT1 (0.62) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL15810154 0.88 AKT1 (0.48) AKT1AKT2AKT3ROCK1PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052098-B1 ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF PROSTATE CANCER NOVARTIS AG (CH) 2020-12-02 EP claimed
EP-2663189-B1 COMBINATION OF BORTEZOMIB WITH AFURESERTIB AND USE THEREOF IN THE TREATMENT OF CANCER NOVARTIS AG (CH) 2018-07-04 EP claimed
EP-2572199-B1 COMBINATION NOVARTIS AG (CH) 2017-03-08 EP claimed
EP-2117523-B1 INHIBITORS OF AKT ACTIVITY GLAXOSMITHKLINE LLC (US) 2014-06-25 EP claimed
EP-4242206-A1 CRYSTALLINE N-{(1-S)-2-AMINO-1-[(3-FLUOROPHENYL)METHYL]ETHYL}-5-CHLORO-4-(4-CHLORO-1-METHYL-1H-PYRAZOL-5-YL)-2-THIOPHENECARBOXAMIDE HYDROCHLORIDE Novartis AG (CH) 2023-09-13 EP disclosed
EP-2400964-A4 CRYSTALLINE N-{(1-S)-2-AMINO-1-[(3-FLUOROPHENYL)METHYL]ETHYL}-5-CHLORO-4-(4-CHLORO-1-METHYL-1H-PYRAZOL-5-YL)-2-THIOPHENECARBOXAMIDE HYDROCHLORIDE GLAXOSMITHKLINE LLC (US) 2012-08-01 EP disclosed
EP-2400964-A1 CRYSTALLINE N-{(1-S)-2-AMINO-1-[(3-FLUOROPHENYL)METHYL]ETHYL}-5-CHLORO-4-(4-CHLORO-1-METHYL-1H-PYRAZOL-5-YL)-2-THIOPHENECARBOXAMIDE HYDROCHLORIDE GlaxoSmithKline LLC (US) 2012-01-04 EP disclosed